TrianglepUMVC3-hIGFBP-2 Multi-epitope… (NCT07495124)
pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine trial for Fallopian Tube Carcinoma (NCT07495124). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with ovarian, fallopian-tube or primary peritoneal cancer after platinum chemotherapy. CA-125 must have normalized after first-line treatment, then risen sufficiently after later treatment, without measurable disease on scans.
The idea: give one carboplatin infusion, then three IGFBP-2 vaccine intradermal injections, four weeks apart. The vaccine aims to train immunity against a protein found in ovarian cancer cells. Researchers track progression. Another vaccine series at eighteen months is conditional.
This phase 2 study plans 26 patients. John Liao leads the recruiting Fred Hutch/University of Washington Seattle site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.